Update on SPYRAL HTN Global Studies and Rationale for New Study Design - Felix Mahfoud, MD

↳ This is a section part of Moment: CRT 2016 Technology & Innovation - Renal Denervation: New Data and Clinical Trial Design Update

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$29.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Update on SPYRAL HTN Global Studies and Rationale for New Study Design presented by Felix Mahfoud, MD at CRT 2016

Add this Moment to your Passport

Learn from this moment and keep it forever.

Add To Passport

$29.99

This moment is included in Simple Premium - Get started for free.

FREE with Simple Premium

Start your 30-day free trial

Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

Interventional Cardiologists
Interventional Fellows
Physicians with an interest in Resistant Hypertension

Session Name: Renal Denervation: New Data and Clincal Trial Design Update

Track: Technology & Innovation

Learning Objectives

Updates in Renal Denervation and Hypertension Therapies

Other Components in this Moment

Long-term Outcome of OUS Renal Denervation Trials - Felix Mahfoud, MD

SYMPLICITY 3 Longterm Outcome and Lessons Learned - Ajay Kirtane, MD, SM

Status of Renal Denervation Studies for Indications Beyond Hypertension, CHF, CKD, Sleep Apnea - Justin Davies, BSc, MBBS, PhD

Update on SPYRAL HTN Global Studies and Rationale for New Study Design - Felix Mahfoud, MD

Update on REINFORCE Study Rationale for Study Design - Michael Weber, MD

ReCor’s Trial Program - Ajay Kirtane, MD, SM

Long-term Outcome and Update on the ENLIGHTEN Study - Vasilios Papademetriou, MD, Dsc

Is There an Unmet Need for Device Treatment for Moderate Hypertension? - Brent Egan, MD

What is the Optimal Device Trial Design for Hypertension Therapy? - Michael Weber, MD

US Preventive Services Task Force Recommendation on ABPM Rationale/ Potential Implications - Michael Weber, MD

How Do I Treat Today’s Patients with Resistant Hypertension in My Practice? - Horst Sievert, MD, FSCAI

What Are the Primary Endpoints for Controlling Hypertension? Office vs. Ambulatory BP - Felix Mahfoud, MD

Why is There US Apathy Towards ABPM: Low Reimbursement or Cognitive Dissonance? - Krishna Rocha-Singh, MD, FSCAI

Cost-effectiveness in Moderate HTN Population - Brent Egan, MD

Loading Simple Education